Naperville, IL -- (SBWIRE) -- 05/07/2014 -- Reportstack, provider of premium market research reports announces the addition of MK-1602 (Migraine) - Forecast and Market Analysis to 2023 market report to its offering
MK-1602 (Migraine) - Forecast and Market Analysis to 2023
Summary
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
MK-1602, under development by Merck, is a calcitonin gene-related peptide (CGRP) receptor antagonist. It is a member of a new class of therapy for the acute treatment of migraine, called the gepants. CGRP is a vasoactive neuropeptide whose receptors are widely distributed in the peripheral and central nervous systems such as the trigeminovascular complex, thalamus, hypothalamus and trigeminal ganglion (Hoffmann and Goadsby, 2012). CGRP has been indicated as a key mediator of migraine pathology by several lines of evidence.
Scope
- Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on MK-1602 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for MK-1602 for the top seven countries from 2012 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Migraine
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of MK-1602 performance
- Obtain sales forecast for MK-1602 from 2012-2023 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).
To view the table of contents for this market research report please visit
http://www.reportstack.com/product/153814/mk-1602-migraine-forecast-and-market-analysis-to-2023.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###